In conclusion, our findings demonstrated that knockdown of lncRNA-TINCR could inhibit the malignant phenotypes of bladder cancer cells, and TINCR may be used as a potential therapeutic target for bladder cancer. This evidence concerns the gene TINCR and urinary bladder carcinoma.